Zoetis Inc. (ZTS) Stock Price: $82.20+3.38 (+4.29%)
The total return cagr for Zoetis Inc. (ZTS) stock is -49.31% over the past 12 months. The 3 year average growth rate is -19.45% and the 5 year cagr is -13.32%. Total return includes dividends reinvested.
The closing share price for Zoetis Inc. (ZTS) stock was $82.20 for Tuesday, June 9, 2026, up +4.29% from the previous day.
ZTS Price Chart
ZTS Key Metrics
See All MetricsZTS Earnings Preview
Next Earnings Date
Aug 4, 2026
56 days away
EPS Estimate
1.86
Revenue Est.
$2.50B
Last Quarter Results
EPS
$1.53
vs Estimate
$1.62
Revenue
$2.26B
vs Estimate
$2.30B
ZTS Analyst Ratings
Consensus Rating
Based on 17 analysts
Average Price Target
$124.59
+51.6% upside
Low
$90.00
Current
$82.20
High
$160.00
ZTS Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $1.63 | N/A | 3 |
| Q2 2027 | N/A | $1.98 | N/A | 3 |
| Q3 2027 | N/A | $1.98 | N/A | 4 |
| Q4 2027 | N/A | $1.79 | N/A | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $7.42 | N/A | 12 |
| FY 2028 | N/A | $8.02 | N/A | 6 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $2.35B | N/A | 3 |
| Q2 2027 | N/A | $2.62B | N/A | 3 |
| Q3 2027 | N/A | $2.62B | N/A | 4 |
| Q4 2027 | N/A | $2.60B | N/A | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $10.17B | N/A | 12 |
| FY 2028 | N/A | $10.67B | N/A | 6 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
ZTS Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1ZTS | $34.46B | $82.20 | +4.29% | -49.31% | -13.32% | +6.37% |
ZTS Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck